In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents

In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents

CDK-1 and PARP-1 play crucial roles in breast cancer progression. Compounds acting as CDK-1 and/or PARP-1 inhibitors can induct cell death in breast cancer with a selective synthetic lethality mechanism. A mixed treatment by means of CDK-1 and PARP-1 inhibitors resulted in radical breast cancer cell...

Full description

Bibliographic Details
Main Authors: Alessia Bono, Gabriele La Monica, Federica Alamia, Francesco Mingoia, Carla Gentile, Daniele Peri, Antonino Lauria, Annamaria Martorana
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
CDK-1
PARP-1
<i>olaparib</i>
<i>dinaciclib</i>
multitarget mechanism
Online Access:https://www.mdpi.com/1422-0067/24/18/13769

Internet

https://www.mdpi.com/1422-0067/24/18/13769

Similar Items